We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-26.25%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$455M
AUM Growth
-$327M
Cap. Flow
+$27.8M
Cap. Flow %
6.12%
Top 10 Hldgs %
79.01%
Holding
161
New
35
Increased
35
Reduced
40
Closed
40

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$28.9M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$5.02M
3
ESPR
Esperion Therapeutics
ESPR
+$1.86M
4
RSLS
ReShape Lifesciences Inc. Common Stock
RSLS
+$1.72M
5
LFWD icon
ReWalk Robotics
LFWD
+$1.65M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$8.71M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$5.7M
3
FOLD
Amicus Therapeutics
FOLD
+$1.87M
4
APTX
Aptinyx Inc. Common Stock
APTX
+$1.19M
5
VKTX icon
Viking Therapeutics
VKTX
+$1.09M

Sector Composition

Rank Sector Weight
1 Miscellaneous 77.68%
2 Healthcare 21.52%
3 Technology 0.35%
4 Consumer Staples 0.21%
5 Financials 0.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVGR
101
DELISTED
Avinger, Inc. Common Stock
AVGR
$34K 0.01%
+37
New +$61.6K
CVM.WS
102
PUT
DELISTED
Cel-Sci Corp Series S
CVM.WS
$32K 0.01%
+110
New –
FCEL icon
103
PUT
FuelCell Energy
FCEL
$1.22B
$31K 0.01%
2
-8
-80% -$2.29K
CTXR icon
104
Citius Pharmaceuticals
CTXR
$15.4M
$29K 0.01%
1,122
+659
+142% +$22.6K
DRRX
105
CALL
DELISTED
DURECT Corp
DRRX
$27K 0.01%
55
-8
-13% -$70
OTLKW
106
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$27K 0.01%
+177,439
New +$22.4K
ONTXW
107
DELISTED
Onconova Therapeutics, Inc. Warrants
ONTXW
$26K 0.01%
660,970
-4,500
-0.7% -$383
BNBX
108
DELISTED
BNB PLUS CORP
BNBX
– –
0
– –
PLUR icon
109
PUT
Pluri
PLUR
$14.4M
$24K 0.01%
4
– –
FCEL icon
110
FuelCell Energy
FCEL
$1.22B
$20K ﹤0.01%
+103
New +$29.5K
ISEE
111
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16K ﹤0.01%
133
– –
IMNN icon
112
Imunon
IMNN
$7.86M
$15K ﹤0.01%
+55
New +$22.8K
MNKD icon
113
MannKind Corp
MNKD
$1.14B
$14K ﹤0.01%
+12,797
New +$21.7K
SOLOW
114
DELISTED
Electrameccanica Vehicles Corp. Ltd. Warrants
SOLOW
$14K ﹤0.01%
30,905
-70,095
-69% -$31.1K
PPBT
115
Purple Biotech
PPBT
$2.8M
$13K ﹤0.01%
10
-4
-29% -$10.1K
SPHS
116
DELISTED
Sophiris Bio, Inc.
SPHS
$10K ﹤0.01%
+12,046
New +$23.7K
SCYX icon
117
SCYNEXIS
SCYX
$43.7M
$8K ﹤0.01%
197
-323
-62% -$21.9K
BNTCW
118
DELISTED
Benitec Biopharma Limited
BNTCW
$7K ﹤0.01%
58,050
– –
PHIOW
119
DELISTED
Phio Pharmaceuticals Corp. Warrants expiring 12/21/2021
PHIOW
$5K ﹤0.01%
+194,959
New +$7.78K
NSPRZ
120
DELISTED
InspireMD, Inc. Series B Warrants
NSPRZ
$2K ﹤0.01%
1,432,133
-415,503
-22% -$1.12K
APDNW
121
DELISTED
Applied DNA Sciences Inc Warrant
APDNW
$2K ﹤0.01%
602,062
-13,981
-2% -$1.29K
ADVM
122
CALL
DELISTED
Adverum Biotechnologies
ADVM
– –
-223
Closed -$1.35M
ADVM
123
PUT
DELISTED
Adverum Biotechnologies
ADVM
– –
-17
Closed -$102K
ALDX icon
124
CALL
Aldeyra Therapeutics
ALDX
$82.6M
– –
-427
Closed -$589K
ALKS icon
125
CALL
Alkermes
ALKS
$7.72B
– –
-571
Closed -$2.42M
3 4
5
6 7

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2018 Portfolio in Review

As of Q4 2018, Sabby Management held 161 positions worth $455M, down 42% from $782M the previous quarter. Its ten largest holdings account for 79% of the portfolio.

Sabby Management deployed $27.8M of net new capital in Q4 2018, opening 35 new positions and adding to 35 existing holdings. Its largest new stake was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.

By sector, the portfolio is most concentrated in Miscellaneous at 78% of assets, down from 84% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Nektar Therapeutics, an estimated $8.71M trimmed.

  • Sabby Management's largest Q4 2018 buy was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.
  • Sabby Management added most to Biogen in Q4 2018, an estimated $28.9M increase.
  • Sabby Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $8.71M.
  • Sabby Management fully exited Amicus Therapeutics in Q4 2018, selling an estimated $1.87M.
  • Sabby Management's ten largest holdings make up 79% of its $455M portfolio in Q4 2018.
  • Sabby Management opened 35 new positions and closed 40 in Q4 2018.
  • Sabby Management's portfolio value fell 42% quarter-over-quarter to $455M.

Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.